Dr Lal PathLabs

April 1, 2019

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of the Company's wholly owned subsidiary PathLabs Unifiers Private Limited, at their meeting held on Monday, April 1, 2019 approved, acquisition of a Proprietorship Concern. i.e. "M/s Bawankar Pathology".

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the **Annexure I** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,
For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Encl.: As above

Annexure I

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	**Name:** M/s Bawankar Pathology **Turnover**: As detailed in Point No. 10
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No, the transaction is not a related party transaction.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company's Subsidiary PathLabs Unifiers Private Limited has decided to acquire 100% of business of M/s Bawankar Pathology with the objective of strengthening its presence in the business.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 3 month
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	Not exceeding INR 5.20 Crores
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Complete Control
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	M/s Bawankar Pathology is a sole-proprietorship firm based out of Bhandara, Maharashtra. Audited turnover for M/s Bawankar Pathology for the last three financial years (Amount in INR Crores): FY16 – INR 1 Cr. FY17 – INR 1.3 Cr FY18 – INR 1.5 Cr.

